Current Status and Future Development of Tools for Prognosis and Prediction - USA

John H. Ward, MD
Professor of Medicine
University of Utah School of Medicine
Huntsman Cancer Institute
October 18, 2009
Outline

• Introductory thoughts
• Prognostic factors and predictive factors
• Computer-generated prognosis
• Gene expression profiles – current status in USA
• Future needs and wants
Assessment of Recurrence Risk: Prognostic Factors & Predictive Factors

- Tumor Size
- Lymph node status
- Tumor Type/Grade
- Lymphatic/Vascular invasion
- Hormone receptor status
- HER2 status
- Gene expression profiling
# Breast Survival

**Effects of Tumor & Nodes on Survival**

<table>
<thead>
<tr>
<th>Tumor Size (cm)</th>
<th>Negative Nodes</th>
<th>1 to 3 Positive Nodes</th>
<th>4 or More Positive Nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.5</td>
<td>99.2%</td>
<td>95.3%</td>
<td>59.0%</td>
</tr>
<tr>
<td>0.5-0.9</td>
<td>98.3%</td>
<td>94.0%</td>
<td>54.2%</td>
</tr>
<tr>
<td>1.0-1.9</td>
<td>95.8%</td>
<td>86.6%</td>
<td>67.2%</td>
</tr>
<tr>
<td>2.0-2.9</td>
<td>92.3%</td>
<td>83.4%</td>
<td>63.4%</td>
</tr>
<tr>
<td>3.0-3.9</td>
<td>86.2%</td>
<td>79.0%</td>
<td>56.9%</td>
</tr>
<tr>
<td>4.0-4.9</td>
<td>84.6%</td>
<td>69.8%</td>
<td>52.6%</td>
</tr>
<tr>
<td>≥ 5.0</td>
<td>82.2%</td>
<td>73.0%</td>
<td>45.5%</td>
</tr>
</tbody>
</table>

BREAST CANCER

5-year survival as function of the number of positive axillary lymph nodes

Breast Cancer v. Other Cancer types

• Well established prognostic features
• Adjuvant therapy clearly advantageous based on numerous trials with long followup
• Application of targeted therapy widely used
• New approaches tested with clinical trials
Prognostic v. Predictive

• Prognostic factors: Correlate with or determine outcome
  – May select patients most likely to recur without adjuvant therapy

• Predictive factors: Reflect the tumor or host response to a specific intervention
  – May help to select the best therapy for a given clinical situation

Not always either/or!!!
Current Targets for Therapy

• Currently include ER, PR, & HER2
• Assays may vary, and accuracy can be lacking: “Who is right when results differ?”
• Always important to verify where the test is being done and review its track record
• Assays may and will change with time.
IHC Testing for HER2 Expression

<table>
<thead>
<tr>
<th>Staining pattern</th>
<th>Score</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>No staining</td>
<td>0</td>
<td>Negative</td>
</tr>
<tr>
<td>Faint incomplete staining of cell membrane in &gt;10% of tumor cells</td>
<td>1+</td>
<td>Trace Negative</td>
</tr>
<tr>
<td>Weak to moderate complete staining of cell membrane in &gt;10% of tumor cells</td>
<td>2+</td>
<td>Weak Positive</td>
</tr>
<tr>
<td>Strong complete staining of cell membrane in &gt;10% of tumor cells</td>
<td>3+</td>
<td>Strong Positive</td>
</tr>
</tbody>
</table>

Figure 4 Scoring method used in the HercepTest IHC assay. Figure courtesy of Kenneth Bloom, MD.
FISH determination of HER2 gene amplification

Figure 6 Distribution of HER2 gene/chromosome 17 ratios in 2,502 breast cancer tumor samples analyzed using the PathVysion FISH method.
Assays may and will change

Hormone Receptors:
- RIA → IHC → Gene expression (?)

HER2 Status
- IHC → FISH → Gene expression (?)

Reasons for change: convenience, expense, accuracy, reproducibility, safety
Cost of one year of Trastuzumab to Huntsman Cancer Institute

- 440 mg vial: ~ $2987
  (¥269,362)

Cost of 17 doses: ~ $50,787
  (¥4,578,860)
Risk Drives Decisions

Tumor Risk

High risk

Low risk

More aggression

Therapy
Reasons for Accurate Prognosis

• Adjuvant chemotherapy has toxicities, and those who don’t need it could avoid unnecessary treatment

• Adjuvant chemotherapy is expensive, both monetarily and emotionally

• If needed, we would like to provide the most refined and directed therapy possible
Computer models assist in defining benefit

• Absolute benefit is different than relative benefit
• Do physicians overestimate or underestimate the effect of adjuvant therapy?
• Do patients really understand the magnitude of benefit – is the “juice worth the squeeze?”
Caveats

- Cannot include all known or unknown prognostic factors
- 10 year relapse or survival is only one measure of outcome
- Guidelines and estimates only

For a more detailed review, see JNCCN 1:189-196, 2003 (April)
Loprinzi and Ravdin
What do you think?

• 45 year-old premenopausal woman
  – Grade 3 infiltrating ductal carcinoma
  – 2.5 cm primary
  – 2 positive nodes
  – ER negative
  – HER2 positive

• What is her risk of relapse at 10 years?
Her Risk of Systemic Relapse at 10 years is ...

1. 20%
2. 40%
3. 60%
4. 80%
Adjuvant! Online – A few issues

- Commonly used in United States
- Not always easy to explain
- May give a false impression of precision
- Cannot account for tumor-specific factors

A good start, but we need more
Gene Expression Profiles

• Most current treatments are based on what the cancer looks like under the microscope
• Appearances can be deceiving!!
• New technology using DNA microarrays enables investigators to look at gene expression and potentially better classify tumors
Gene expression patterns in breast cancers
“How does truth in a blue and pink world compare to truth in a red and green world?”

- Anon, re: gene expression profiling
RNA Expression Profiling

Protein Expression (IHC)

**ER**

**RNA Expression Profiling**

**Red** = relative increase in RNA

**Green** = relative decrease in RNA

**Black** = no change

**Brown** = antigen present

*Image courtesy of Susan Lester, MD, PhD*  
*DFCI / BWH*
Comparison of Risk Stratification Strategies
LN Negative Patients

van de Vijver, et al. NEJM 2002
Gene Expression Profiles

“Biology is Destiny”

“Biology is King”
Gene Expression Profiling

- **Oncotype DX** – 21 gene assay
- **MammaPrint** – 70 gene assay
- Technical differences
- Current data based on strong retrospective analyses
- Other techniques and assays *sure* to follow
OncoType DX Report

RESULTS

Recurrence Score = 16

CLINICAL EXPERIENCE: PROGNOSIS FOR NODE NEGATIVE, ER-POSITIVE PATIENTS

The Clinical Validation study included female patients with Stage I or II, Node Negative, ER-Positive breast cancer treated with 5 years of tamoxifen. Those patients who had a Recurrence Score of 16 had an Average Rate of Distant Recurrence of 10% (95% CI: 7%-13%).

The following results are from a clinical validation study of 668 patients from the NSABP B-14 study. N Engl J Med 2004; 351: 2817-26.

Recurrence Score vs Distant Recurrence in NODE NEGATIVE, ER-Positive Breast Cancer Prognosis
CLINICAL EXPERIENCE: CHEMOTHERAPY BENEFIT FOR NODE NEGATIVE, ER-POSITIVE PATIENTS

The following results are from a clinical study involving 851 patients from the NSABP B-20 Study. The study included female patients with Stage I or II, Node Negative, ER-Positive breast cancer. Patients were randomized to either tamoxifen alone or tamoxifen plus CMF or MF Chemotherapy. For patients in the pre-specified group with Recurrence Scores = 31, the group average 10-year rates (95% CI) of distant recurrence were 40% (25%, 54%) for Tam alone and 12% (6%, 18%) for Tam + CMF/MF. J Clin Oncol. 2000, 24(23): 3720-34.

NODE NEGATIVE, ER-Positive Breast Cancer
Chemotherapy Benefit
OncoType DX Report

Quantitative Single Gene Report

The OncoType DX assay uses RT-PCR to determine the RNA expression of the genes below. These results may differ from ER, PR, or HER2 results reported using other methods or reported by other laboratories. The ER, PR, and HER2 Scores are also included in the calculation of the Recurrence Score.

**ER Score:** 9.6  Positive

The ER Score positive/negative cut-off of 6.5 units was validated from a study of 761 samples using the 1D5 antibody (immunohistochemistry) and 607 samples using the SP1 antibody (immunohistochemistry). The standard deviation for the ER Score is less than 0.5 units.

Clinical Experience:
For ER positive breast cancer, the magnitude of tamoxifen benefit increases as the ER Score increases from 6.5 to >12.5.

Please note: The Average Rate of Distant Recurrence reported on Page 1 based on the Recurrence Score was determined in patients who received 5 years of tamoxifen treatment and takes into account the magnitude of tamoxifen benefit indicated by the ER Score.

**PR Score:** 8.8  Positive

The PR Score positive/negative cut-off of 5.5 units was validated from a study of 761 samples using the PR638 antibody (immunohistochemistry) and another study of 607 samples using the PR638 antibody (immunohistochemistry). The standard deviation for the PR Score is less than 0.5 units.

**HER2 Score:** 8.9  Negative

The HER2 positive cut-off of >11.5 units, equivocal range from 10.7 to 11.4 units, and negative cut-off of < 10.7 units were validated from concordance studies of 756 samples using the HercepTest™ assay (immunohistochemistry) and another study of 508 samples using the PathVysion™ assay (FISH). The standard deviation for the HER2 score is less than 0.5 units.
Sample MammaPrint Report

Results

Pathology findings, H&E staining
Sample contains an average of 45% tumor, see picture

The sample is classified as: LOW RISK

Analysis Description

The breast cancer tissue sample submitted was analyzed by MammaPrint®, a gene expression analysis of 70 prognostic genes that has been validated to correlate with high or low outcome risk for distant metastasis in women with breast cancer.

Interpretation

In the reference group as published¹, lymph node-negative patients classified as Low Risk had a 13% chance to develop distant metastases at 10 years, without adjuvant treatment. The patients classified as High Risk had a 56% chance to develop distant metastases at 10 years, without adjuvant treatment. MammaPrint® has been independently validated and shown to provide independent prognostic information to clinicopathological risk assessment for patients with lymph node-negative breast cancer².

International validation in European patients³ showed that patients with a “Good signature” had a probability of 90% of metastasis-free survival at 10 years. Patients with a “Poor signature” had a probability of 70% metastasis-free survival at 10 years.

H&E Staining

Patient ID
Gene Expression Profiles

- Gene expression profiles may potentially provide better prognostic information.
- Studies show promise, but require confirmation and improved nomenclature.
- At the moment, the assays are helpful in a minority of patients.

A good start, but we need more.
More data will be coming, due to the strength of randomized, prospective trials.
Evaluate Clinical-Pathological risk and 70-gene signature risk

Clinical-pathological and 70-gene both HIGH risk

- Clin-Path HIGH 70-gene LOW
- Clin-Path LOW 70-gene HIGH

55%

Discordant cases

Clinical-pathological and 70-gene both LOW risk

13%

N=780

N=1920

R-T

Use Clin-Path risk to decide Chemo or not

Use 70-gene risk to decide Chemo or not

Chemotherapy

Potential CT sparing in 10-15% pts

Endocrine therapy

N=3300

55%

32%

EORTC 10041 BIG 3-04 trial MINDACT TRIAL DESIGN

6,000 Node - & 1-3 N+ women

EORTC 10041 BIG 3-04 trial MINDACT TRIAL DESIGN

N=3300

55%

32%

13%

N=780

Clinical-pathological and 70-gene both HIGH risk

- Clin-Path HIGH 70-gene LOW
- Clin-Path LOW 70-gene HIGH

55%

Clinical-pathological and 70-gene both LOW risk

13%

N=780

Clinical-pathological and 70-gene both LOW risk

13%

N=780

Clinical-pathological and 70-gene both LOW risk

13%

N=780

Clinical-pathological and 70-gene both LOW risk

13%

N=780

Clinical-pathological and 70-gene both LOW risk

13%

N=780

Clinical-pathological and 70-gene both LOW risk

13%
Node N-, ER+ Breast Cancer

Register Specimen banking

OncoType DX® Assay

RS < 10
Hormone Therapy Registry

RS 11-25
Randomize Hormone Rx vs Chemotherapy + Hormone Rx

RS > 25
Chemotherapy + Hormone Rx

Primary study group
Current Usage of Prognostic and Predictive Factors in USA

• Clinical and pathologic parameters remain important
• Hormone receptor and HER2 status mandatory
• Gene expression profiles:
  – ER positive, node negative *when a chemotherapy choice may be affected*
  – No consensus on use in ER+, Node +, patients
Prognostic vs. Predictive

Hippocrates, *On the Prognostics, Book I*

- PROGNOSTIC: “It appears to me a most excellent thing for the physician to cultivate Prognosis; for by foreseeing and foretelling…he will be the more readily believed to be acquainted with the circumstances of the sick.”

- PREDICTIVE: “It is impossible to make all the sick people well; this, indeed, would have been better than to be able to foretell what is going to happen.”
The Ideal Prognostic and Predictive Test

- Accurate
- Verifiable
- Reproducible
- Timely
- Acceptable cost
- Convenient
The Ideal Prognostic and Predictive Test

• Adaptable
  – Able to incorporate new information as it becomes available
  – Able to assist in defining type of therapy to be given
  – Able to subclassify tumors
  – Able to quantitate new targets
  – Able to incorporate pharmacogenomics
Breast Cancer Complexity

What We Wish …

What We Have …

Courtesy of Antonio Wolff, MD
Confusion and Chaos
Coherence & Serenity
Thank you!

Wasatch Mountains - Utah